UNC Project- Malawi Cancer Program
WHY MALAWI?
The UNC Project- Malawi Cancer Program is well-positioned to catalyze a broad, coordinated cancer control effort in Malawi, and address key scientific questions related to cancer in sub-Saharan Africa. Read More
OUR PRIORITIES
We aim to develop sufficient internal capacity such that Malawi can become a leader of cancer care and research in low-resource settings, as it has long been for HIV care and treatment. Read More
OUR PARTNERS
Collaboration is an important component of what we do and our success is supported by a remarkable cancer research network of diverse and accomplished partner institutions. Read More
Recent Scientific Outputs
-
Improving Access to Self-Expanding Metal Stents for Patients With Esophageal Cancer in Eastern Africa: A Stepwise Implementation Strategy
January 2021-The eastern corridor of Africa is affected by a high burden of esophageal cancer (EC), with > 90% of patients presenting with advanced disease. Self-expanding metal stents (SEMS) have been previously reported as safe and effective for palliation of malignant dysphagia in resource-limited settings; however, access is limited throughout Eastern Africa. In response to … Continued
-
Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial
July 2021- There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL in Malawi. This prospective, … Continued
-
Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis
July 2021- Cost-effectiveness data for cancer treatment are needed from sub-Saharan Africa, where diffuse large B-cell lymphoma (DLBCL) is a common, curable cancer. In high-income countries, the standard of care for DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemoimmunotherapy. Rituximab is often not available in sub-Saharan Africa due to perceived unaffordability, and treatment … Continued
Recent News
-
UNC Awarded NCI Grant to Strengthen Institutional Capacity for Cancer Research in Malawi
University of North Carolina at Chapel Hill was one of four institutions to be awarded a National Cancer Institute D43 grant to strengthen institutional capacity for cancer research in LMIC’s. The 5-year grant strengthens the partnership of the UNC Institute for Global Health and Infectious Diseases and the UNC Lineberger Comprehensive Cancer center and establishes … Continued
-
UNC cancer researchers find combination chemotherapy beneficial and cost-effective in sub-Saharan Africa
Researchers at UNC Project Malawi and the UNC Lineberger Comprehensive Cancer Center demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective. The economic finding appeared July 22, 2021, in … Continued
-
Cancer Program Host’s Its 3rd Malawi Cancer Symposium
“Together Against Cancer” The UNC Project Cancer Program hosted its 3rd Annual Malawi Cancer Symposium on May 26th-27th, 2021. The symposium was organized by the UNC Project Malawi Cancer Program in collaboration with the Malawi Ministry of Health and with funding from the National Institute of Health. Due to Covid-19 restrictions, the 2 day symposium … Continued